These drugs and the biotechs that make them could be on the way to tremendous success in the near future.
News & Analysis: Bluebird Bio
An approval for Zynteglo is imminent.
A new payment proposal that directly affects hospitals could also boost sales of some expensive new cancer therapies.
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
No-news anxiety-selling seems to be to blame for the biotech's woes.
These fast-growing companies are leveraging advances in genetic insight in ways that could pay off big for investors.
A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.
The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.
The biotech is on the verge of its first approval, with three more in the works.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.